Application value of volumetric modulated arc therapy combined with zoledronic acid in treatment of vertebral metastasis
10.3760/cma.j.issn.1006-9801.2018.11.004
- VernacularTitle:容积旋转调强放疗联合唑来膦酸在椎体转移瘤治疗中的应用价值
- Author:
Wenju SUN
1
;
Chengyu SHI
;
Xiaoyan MA
;
Yuan YAO
Author Information
1. 266042,青岛市中心医院放疗二科
- Keywords:
Vertebral metastases;
Volumetric modulated arc therapy;
Zoledronic acid
- From:
Cancer Research and Clinic
2018;30(11):735-738
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the application value of volumetric modulated arc therapy (VMAT) combined with zoledronic acid in treatment of vertebral metastases. Methods A total of 58 patients with vertebral metastasis in Qingdao Central Hospital from January 2015 to June 2017 were extracted according to simple random sampling method. The data of 58 patients were analyzed retrospectively, and they were divided into 2 groups according to the different radiotherapy technology. The study group (28 cases) received VMAT combined with zoledronic acid treatment, and the control group (30 cases) received general radiotherapy combined with zoledronic acid treatment. The efficacy and tissue damage of the patients in both groups were compared according to the evaluation criterion including the local control rate, pain relief rate, local progression-free survival rate and exposure of the spinal cord. Results The local control rates were 92.9 ％ (26/28) and 73.3 ％ (22/30) respectively in the study group and the control group (χ2= 3.869, P=0.049). The pain relief rates were 96.4 ％ (27/28) and 76.7 ％ (23/30) respectively (χ2= 4.757, P= 0.029). The local progression-free survival rates of 3-month were 85.7 ％ (24/28), 60.0 ％ (18/30) respectively (χ2=4.794, P= 0.029) and the local progression-free survival rates of 6-month were 78.6 ％ (22/28), 50.0 ％(15/30) in the study group and the control group (χ2=5.119, P=0.024). The exposure of the spinal cord was (29.80±0.88) Gy and (39.90±0.20) Gy, respectively (t= -61.083, P= 0.000). Conclusion VMAT combined with zoledronic acid can improve the local control rate, pain relief rate, local progression-free survival rate, and reduce the exposure of the spinal cord.
